Details of the Drug Combination

General Information of Drug Combination (ID: DCLLH17)

Drug Combination Name
Indazole derivative 5 Altretamine
Indication
Disease Entry Status REF
High grade ovarian serous adenocarcinoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R Altretamine   DMKLAYG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: OVCAR-8
Zero Interaction Potency (ZIP) Score: 1.11
Bliss Independence Score: 5.57
Loewe Additivity Score: 4.55
LHighest Single Agent (HSA) Score: 4.08

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Altretamine
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Approved [2]
Altretamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DC7X4TY MOLT-4 Investigative [5]
Chronic myelogenous leukemia DCFNHSB K-562 Investigative [5]
Renal cell carcinoma DCRWF3X SN12C Investigative [5]
Carcinoma DCLJNXC MCF7 Investigative [6]
Invasive ductal carcinoma DCGX5DQ BT-549 Investigative [6]
Adenocarcinoma DCM7E7J NCIH23 Investigative [1]
High grade ovarian serous adenocarcinoma DCFVWCF OVCAR-5 Investigative [1]
Melanoma DCGEU84 SK-MEL-2 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.